Steatosis in chronic hepatitis C: Prevalence and predictive factors

Authors

  • Asma Ouakaa-Kchaou Service de Gastro-entérologie Hôpital H. Thameur Tunis
  • Dalila Gargouri Service de Gastro-entérologie Hôpital H. Thameur Tunis
  • Asma Kochlef
  • Achraf Debbiche
  • Héla Elloumi
  • Mouna Ghouma
  • Afef Kilani
  • Malika Romani
  • Jamel Kharrat
  • Abdeljabbar Ghorbel

Keywords:

Chronic hepatitis C; steatosis

Abstract

Background: Patients with hepatitis C virus seem to often have hepatic steatosis.
Aim: To assess the prevalence and the predictive factors of steatosis during chronic hepatitis C.
Methods: We studied 50 HCV RNA positive subjects, who had liver biopsy performed. Steatosis was searched and patients were divided into to groups according to the presence or not of steatosis.
Results: On liver biopsy, 28 patients (56%) had steatosis. Multivariante analysis showed that steatosis was associated with age 58 years > 1,1 μmol/l, odds ratio 2 (95% CI 1.48 – 2.6; p= 0.02) and triglycerides level, odds ration 4,22 (95% CI 1.05 – 16.98; p = 0,03.
Conclusion: In this study, steatosis was significantly associated with metabolic factors.

Downloads

Download data is not yet available.

References

Cross TJ, Quaglia A, Hughes S, Joshi D, Harrison PM. The Impact of Hepatic Steatosis on the Natural History of Chronic Hepatitis C Infection. J Viral Hep 2009; 16:492-9.

Scheuer PJ, Ashrafzadeh P, Sherlock S et al. The pathology of hepatitis C. Hepatology 1993; 15: 567-71.

Lonardo A, Adinolfi LE, Loria P, et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-97.

Goodman ZD, Ischak KG. Histopathology of hepatitis C virus infection. Semin Liver Dis 1995; 15: 70-81.

Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host-and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998; 29: 198-206.

Hui JM, Kench J, Farrell GC, et al. Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol 2002; 17: 873-81.

Hwang SJ, Luo JC, Chu CW, et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol 2001; 16: 190-5.

Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106-15.

Hézode C, Castéra L, Chouteau P, Dhumeaux D, Pawlotstky JM. Stéatose et hépatite C. Gastroenterol Clin Biol 2003; 27: 1091-5.

Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology 2005; 42:310- 6.

Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-90.

Poynard T, Ratziu V, McHutchison J et al. Effect of treatment with peg interferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.

Camma C, Bruno S, Di Marco V, et al. Insulin resistance is associated with steatosis in non diabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006; 43:64-71.

Cornianu M, Dema A, Taban S, Lazar D, Lazar E, Costi S. Hepatic steatosis associated with hepatitis C virus infection. Rom J Morphol Embryol. 2005; 46:283-9.

Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation and fibrosis in chronic hepatitis C: A meta-Analysis of individual patient data. Gastroenterology 2006; 130: 1636-42.

Fromenty B, Mansouri A, Degoul F, Demmeillers C, Gaou I, Pessayre D. Vieillissement, alcool et mitochondries. Gastroenterol Clin Biol 1998; 22: 59-72.

Hickman IJ, Clouston AD, Macdonald GA, et al. effect of Weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51: 89-94.

Monto A, Alonzo J, Watson J, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36: 729-36.

Serfaty L, Poujol-Robert A, Carbonell N et al. Effect of the interaction between steatosis and alcohol intake on liver fibrosis progression in chronic hepatitis C. Am J Gastroenterol 2002; 97: 1807-12.

Westin J, Nordlinder H, Lagging M, Norkrans G, Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 2002; 37: 837-42.

Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T, LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 2003; 39: 1049-55.

Gordon A, McLean CA, Pederson JS, Bailey MJ, Roberts SK. Hepatic steatosis in chronic hepatitis B and C: Predictors, distribution and effect on fibrosis. J Hepatol 2005; 43: 38-44.

Koike K, Miyoshi H. Oxidative stress and hepatitis C viral infection. Hepatol Res 2006; 34: 65-73.

Tsutsumi T, Suzuki T, Shimoike T, et al. Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology 2002; 35: 937-46.

Unger RH, Orci L. Lipoapoptosis: its mechanism and its disease. Biochim Biophys Acta 2002; 1585: 202-12.

Bjoro K, Bell H, Hellum KB, et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomised multicentre study. Scand J Gastroenterol 2002; 37: 226-32.

Fabris P, Floreani A, Carlotto A, et al. Alcohol is an important co-factor for both steatosis and fibrosis in Northern Italian patients with chronic hepatitis C. J Hepatol 2004; 41: 644-51.

Hézode C, Lonjon I, Roudot-Thoraval F, et al. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: A prospective study. Aliment Pharmacol Ther 2003; 17: 1031-7.

Perlemuter G, Letteron P, Carnot F, et al. Alcohol and hepatitis C virus core protein additively increase lipid peroxidation and synergistically trigger hepatic cytokine expression in a transgenic mouse model. J Hepatol 2003; 39: 1020-7.

Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6664 patients. Hepatology 1997; 26: 485-90.

Rubbia-Brandt L, Fabris P, Paganin S et al. steatosis affects chronic hepatitis C progression in a genotype-specific way. Gut 2004; 53: 406-12.

Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997; 25: 735-9.

Adinolfi LE, Gambardella M, Andreana A et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.

Hourigan LF, Macdonald GA, Purdie D et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215-9.

Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34: 428-34.

Downloads

Published

2011-12-09

Issue

Section

Original articles